Exploring sociodemographic and economic factors that promote adverse drug reactions reporting by patients.

Autor: Inácio P; Clinical Pharmacy Group, Division of Pharmacology and Pharmacotherapy, Faculty of Pharmacy, University of Helsinki, Finland. Electronic address: pedro.inacio@helsinki.fi., Gomes JJ; Department of Statistics and Operational Research, Faculty of Sciences, University of Lisbon, Portugal. Electronic address: jjgomes@ciencias.ulisboa.pt., Airaksinen M; Clinical Pharmacy Group, Division of Pharmacology and Pharmacotherapy, Faculty of Pharmacy, University of Helsinki, Finland. Electronic address: marjaairaksinen@gmail.com., Cavaco A; iMed.ULisboa Research Institute for Medicines and Pharmaceutical Sciences, Faculty of Pharmacy, University of Lisbon, Portugal. Electronic address: acavaco@ff.ulisboa.pt.
Jazyk: angličtina
Zdroj: Health policy (Amsterdam, Netherlands) [Health Policy] 2018 Mar; Vol. 122 (3), pp. 263-268. Date of Electronic Publication: 2017 Nov 08.
DOI: 10.1016/j.healthpol.2017.10.004
Abstrakt: Background: Adverse drug reactions (ADRs) are recognized as a leading cause of morbidity and mortality, and an important cost factor to health systems. Patient reporting of ADRs has emerged as an important topic in recent years but reporting rates are still low in many countries.
Objective: To explore different countries' sociodemographic and economic features as explanatory factors for population ADRs reporting, including the propensity of patients' reporting to pharmacovigilance authorities.
Methods: Cross-sectional observational design. A data set of 42 global sociodemographic and economic factors for 44 countries were retrieved, as to analyse statistical associations between these factors and the patient reporting rate of ADRs. Multivariate logistic regression models were designed to identify the predictive covariables.
Results: Health investment indicators, such as per capita public health expenditure, hospital bed density and under five mortality rate were the relevant factors responsible to discriminate between countries that have higher patient reporting rates.
Conclusions: This study shows that healthcare investment-related factors help explain the propensity of patients to report suspected ADRs, while pharmacovigilance features were not directly associated with higher patient participation in drug safety mechanisms. Although general, these results point a direction in further policy making to improve resources allocation concerning the promotion of patients' participation.
(Copyright © 2017 Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: